MAGE A3 TCR

Drug Profile

MAGE A3 TCR

Alternative Names: Anti-MAGE A3 HLA-A-01-restricted TCR; Anti-MAGE-A3-DP4-TCR; Anti-MAGE-A3-TCR

Latest Information Update: 17 Oct 2016

Price : $50

At a glance

  • Originator National Cancer Institute (USA)
  • Developer Kite Pharma; National Cancer Institute (USA)
  • Class Cell therapies
  • Mechanism of Action Gene transference; MAGEA-3-protein-modulators; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 05 Oct 2016 National Cancer Institute reinitiates patient enrolment in a phase-I/II trial in Solid tumours (Second-line therapy or greater, Combination therapy, Late-stage disease) in USA (IV) (NCT02111850)
  • 16 Apr 2016 Interim efficacy data from a phase I/II trial in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 12 Apr 2016 National Cancer Institute suspends patient enrolment in a phase-I/II trial in Solid tumours (Second-line therapy or greater, Combination therapy, Late-stage disease) in USA (IV) (NCT02111850)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top